Growth Metrics

Merck (MRK) Net Income (QoQ) (2009 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -242.10%
Dec 31, 2025 -48.82%
Sep 30, 2025 30.69%
Jun 30, 2025 -12.92%
Mar 31, 2025 35.82%
Dec 31, 2024 18.44%
Sep 30, 2024 -42.12%
Jun 30, 2024 14.56%
Mar 31, 2024 488.83%
Dec 31, 2023 -125.81%
Sep 30, 2023 180.01%
Jun 30, 2023 -310.16%
Jun 30, 2021 -24.03%
Mar 31, 2021 -16.44%
Dec 31, 2020 -15.24%
Sep 30, 2020 -6.66%
Jun 30, 2020 -79.47%
Mar 31, 2020 278.04%
Dec 31, 2019 -194.81%
Sep 30, 2019 -27.87%
Jun 30, 2019 -7.62%
Mar 31, 2019 60.97%
Dec 31, 2018 -9.19%
Sep 30, 2018 14.10%
Jun 30, 2018 131.58%
Mar 31, 2018 171.39%
Dec 31, 2017 -1,935.29%
Sep 30, 2017 -102.61%
Jun 30, 2017 25.39%
Mar 31, 2017 365.08%
Dec 31, 2016 -126.83%
Sep 30, 2016 80.98%
Jun 30, 2016 6.99%
Mar 31, 2016 15.07%
Dec 31, 2015 -46.37%
Sep 30, 2015 166.13%
Jun 30, 2015 -28.18%
Mar 31, 2015 -86.93%
Dec 31, 2014 770.19%
Sep 30, 2014 -58.58%
Jun 30, 2014 17.45%
Mar 31, 2014 112.39%
Dec 31, 2013 -29.13%
Sep 30, 2013 22.99%
Jun 30, 2013 -42.14%
Mar 31, 2013 70.28%
Dec 31, 2012 -46.17%
Sep 30, 2012 -3.13%
Jun 30, 2012 3.00%
Mar 31, 2012 14.52%
Dec 31, 2011 -10.50%
Sep 30, 2011 -16.07%
Jun 30, 2011 91.78%
Mar 31, 2011 164.75%
Dec 31, 2010 -544.62%
Sep 30, 2010 -52.31%
Jun 30, 2010 117.27%
Mar 31, 2010 -97.24%
Dec 31, 2009 1,390.81%
Sep 30, 2009 -356.22%
Jun 30, 2009 -50.92%